Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms

<h4>Background</h4> The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Justin Sinclair, Laura Collett, Jason Abbott, David W. Pate, Jerome Sarris, Mike Armour
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a2f6d2eb95084736a41dca68b7cea271
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2f6d2eb95084736a41dca68b7cea271
record_format	dspace
spelling	oai:doaj.org-article:a2f6d2eb95084736a41dca68b7cea2712021-11-04T06:19:45ZEffects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms1932-6203https://doaj.org/article/a2f6d2eb95084736a41dca68b7cea2712021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547625/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain. <h4>Methods</h4> A retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded. <h4>Results</h4> A total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion. <h4>Conclusions</h4> Cannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.Justin SinclairLaura CollettJason AbbottDavid W. PateJerome SarrisMike ArmourPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Justin Sinclair Laura Collett Jason Abbott David W. Pate Jerome Sarris Mike Armour Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
description	<h4>Background</h4> The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain. <h4>Methods</h4> A retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded. <h4>Results</h4> A total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion. <h4>Conclusions</h4> Cannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.
format	article
author	Justin Sinclair Laura Collett Jason Abbott David W. Pate Jerome Sarris Mike Armour
author_facet	Justin Sinclair Laura Collett Jason Abbott David W. Pate Jerome Sarris Mike Armour
author_sort	Justin Sinclair
title	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
title_short	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
title_full	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
title_fullStr	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
title_full_unstemmed	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
title_sort	effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/a2f6d2eb95084736a41dca68b7cea271
work_keys_str_mv	AT justinsinclair effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms AT lauracollett effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms AT jasonabbott effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms AT davidwpate effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms AT jeromesarris effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms AT mikearmour effectsofcannabisingestiononendometriosisassociatedpelvicpainandrelatedsymptoms
_version_	1718445106549227520

Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms

Ejemplares similares